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recycled for downstream metabolism (1). Among the three 
major kinds of autophagy, macroautophagy, microautoph-
agy, and chaperone-mediated autophagy, macroautophagy 
is the most prevalent form and, thus, commonly referred to 
as autophagy (2, 3). Over the past decade, research efforts 
regarding this ancient biological process have been revived 
due to the realization that alterations in autophagy play 
crucial pathological roles in many diseases (4, 5) for which 
current therapeutic means are limited. While many basic 
aspects of autophagy have been unraveled, little has been 
translated into clinical benefit, and no autophagy-modulating 
therapies have been approved for clinical use.
The autophagy process starts with the formation of a dou-
ble-membrane autophagosome, which engulfs cytoplasmic 
materials. Autophagosomes are targeted to the lysosomal 
compartment and single-membrane autolysosomes are gen-
erated in which the sequestered cargos are degraded in the 
highly acidic environment and the resulting simple products 
are reused (6, 7). There are many molecules involved in au-
tophagy, including Beclin-1 (involved in vesicle nucleation); 
Atg5, Atg7, and Atg16L1 (involved in vesicle elongation); 
and LC3 (involved in the expansion of autophagosome 
membrane and autophagosome-lysosome fusion) (8). Au-
tophagy occurs in almost all cell types, including macro-
phages. Macrophages primarily use phagocytosis as the first 
line of defense against exogenous pathogens and endoge-
nous waste products. They adopt autophagy to process bulky 
materials (e.g., damaged mitochondria and excessive lipids) 
in unfavorable microenvironments, thus mitigating cytotox-
icity. Recently, autophagy has been shown to play a critical 
role in inflammatory responses in macrophages by interact-
ing with inflammasomes or directly targeting pro-interleukin 
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The purity of UA was determined by HPLC as >98% by Dr. Qian 
Wang at the Department of Chemistry and Biochemistry, University 
of South Carolina. LPSs, Wortmannin, and bafilomycin were pur-
chased from Sigma-Aldrich (St. Louis, MO). Pam3CSK4 was ob-
tained from Invitrogen (Carlsbad, CA). Rabbit anti-IL-1 antibody 
(catalog number 12507) and mouse anti-IL-1 antibody (catalog 
number 12242) were from Cell Signaling Technology (Danvers, 
MA); rabbit anti-LC3 (catalog number L7543) and rabbit anti-
actin antibodies (catalog number A2066) were from Sigma-
Aldrich; rabbit anti-ABCA1 antibody (catalog number NB400-105) 
and rabbit anti-ABCG1 antibody (catalog number 400-132) were 
from Novus Biologicals (Littleton, CO); HRP-conjugated goat anti-
rabbit IgG (catalog number A2315) and goat anti-mouse IgG (cata-
log number L0312) were from Santa Cruz (Dallas, TX); rat 
monoclonal MOMA2 (catalog number 3451) was from Abcam 
Inc. (Cambridge, MA); Alexa Fluor®488-labeled donkey anti-goat 
IgG (catalog number 1298475) and Alexa Fluor® 555 goat anti-
rabbit IgG (catalog number 1683674) were from Life Technolo-
gies (Waltham, MA). Primers were synthesized by Invitrogen.
Cell culture and manipulation
RAW264.7 cells were obtained from ATCC (Rockville, MD) 
and were maintained in DMEM with10% FBS. Thioglycollate-
elicited mouse peritoneal macrophages (pMs) were obtained 
as previously described (33) and cultured in DMEM with 10% 
FBS for 2 h, unattached cells were washed away, and the attached 
macrophages were then further cultured in appropriate me-
dium. For LPS treatment, pMs were incubated for 6–24 h in the 
culture medium (DMEM with 0.25% FBS) with an addition of 
LPS and UA at the indicated concentrations. The cells were then 
washed with Dulbecco’s PBS twice before being lysed for total 
RNA or protein extraction. Raw 264.7 cells and pMs were 
treated with UA (10 M) and TLR1/2 ligand Pam3CSK4 (500 
ng/ml) or TLR4 ligand LPS (100 ng/ml) either alone or in com-
bination, as indicated, for 6 h. In some experiments, cells were 
exposed to various autophagy modulators for 1 h prior to UA 
treatment, such as 500 nM Wortmannin to inhibit PI3K or 100 nM 
bafilomycin to inhibit degradation of LC3.
Mice
All mice were purchased from the Jackson Laboratory (Bar Har-
bor, ME) and housed in the University of South Carolina Animal 
Research Facility. All animal experiments were carried out in com-
pliance with the National Institutes of Health guidelines and were 
approved by the Institutional Animal Care and Use Committee of 
the University of South Carolina. In the serum IL-1 measurement 
experiment, C57BL/6 mice were randomly grouped (four mice in 
the control group, five mice in the LPS group, and five mice in LPS 
plus UA group) and were injected intraperitoneally with either 
LPS (20 g/mouse) alone or together with UA (50 mg/kg), and 
blood was taken after 16 h for analysis of serum IL-1 by ELISA 
using kits from eBioscience (catalog number BMS6002INST; San 
Diego, CA). For atherosclerosis studies, female LDLR/ mice 
were fed a Western diet and treated with UA for 11 weeks before 
they were euthanized for analysis. The Western diet contained 
21% (wt/wt) anhydrous milkfat, 34% (wt/wt) sucrose, and a total 
of 0.2% (wt/wt) cholesterol (diet number TD.88137; Harlan Labo-
ratories, Indianapolis, IN).
MTT assay
The pMs were cultured in phenol red-free medium in 24-
well plates. Cytotoxicity of UA was determined using an MTT cell 
viability assay kit from ATCC BioproductsTM (Manassas, VA) fol-
lowing the manufacturer’s instructions. The 96-well microplates 
were read using a SpectraMax M5 microplate reader (Molecular 
Devices, Sunnyvale, CA); absorbance at 570 nm was measured.
(IL)-1 and thereby limiting IL-1 production (9–11). Au-
tophagy, in the form of lipophagy, contributes to macro-
phage cholesterol homeostasis by cooperating with lysosomes 
in presenting free cholesterol (FC) for apoAI-mediated cho-
lesterol efflux (12–14). Moreover, when macrophages are 
doomed to die, macrophage autophagy also appears to play 
a role in facilitating efferocytosis (a process in which apop-
totic cells are phagocytosed and removed) (15, 16).
Lipid-laden macrophages play a crucial role in the initia-
tion of atherogenesis, and inflammatory responses of macro-
phages are a driving force for atherosclerotic progression 
and plaque growth (17–21). Unbalanced macrophage foam 
cell apoptosis and efferocytosis lead to necrotic core for-
mation in advanced plaques and plaque instability (22). 
Recently, limited but convincing studies have shown that 
macrophage autophagy is atheroprotective by substantially 
altering all these aspects, including the enhancement of cho-
lesterol efflux, suppression of inflammation, and improve-
ment of efferocytosis (11, 15, 23). Evidence showing that 
atherosclerosis progression is accompanied by increasing de-
fects in macrophage autophagy provides further enthusiasm 
regarding the possibility that enhancement of macrophage 
autophagy may be an effective way to reduce or reverse ath-
erosclerosis. However, currently known autophagy inducers, 
including mTOR inhibitors and toll-like receptor (TLR)7 
ligands, are less than ideal therapeutics in the context of ath-
erosclerosis, due to hyperlipidemic (24) and pro-inflammatory 
effects, respectively (25). Therefore, the search for new mac-
rophage autophagy stimuli is urgent.
Ursolic acid (UA), a natural pentacyclic triterpene 
carboxylic acid found in various plants, is present in the hu-
man diet and possesses a wide range of biological functions, 
such as anti-oxidation, anti-inflammation (26), anti-cancer 
(27), and anti-hyperlipidemia (28). Some studies have re-
ported that UA reduces obesity, glucose intolerance, and 
fatty liver (29, 30). These beneficial properties are of appar-
ent value for the treatment of atherosclerosis, although the 
underlying molecular mechanisms are largely unknown. 
Indeed, limited animal studies have shown the potential 
anti-atherogenic effects of UA (31). Our recent finding that 
UA promotes cancer cell autophagy (32) prompted us to 
determine whether this autophagy-enhancing function also 
holds true in macrophages. To this end, we performed 
both in vitro and in vivo studies and found that UA en-
hances macrophage autophagy, suppresses lipopolysac-
charide (LPS)-induced IL-1 production and secretion, 
and promotes cholesterol efflux from acetylated (Ac)LDL-
loaded macrophages. Furthermore, we found that UA at-
tenuated atherogenesis in LDLR/ mice fed a Western 
diet. Our results suggest that UA may be developed as a new 
anti-atherogenic agent by virtue of its ability in enhancing 
macrophage autophagy in an atherogenic environment.
MATERIALS AND METHODS
Materials and reagents
UA (C30H48O3, molecular weight 456.70 Da) was purchased from 
Changsha Luyuan Bio-Technology Co., Ltd. (Changsha, China). 
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and permeabilized for 10 min with Triton X-100 (0.1% in PBS). All 
subsequent steps were conducted at room temperature. The cells 
were blocked with 0.01 M glycine/PBS three times, 30 min each 
time, and then with 5% BSA in PBS for 1 h and stained with primary 
antibody (rabbit anti-LC3 or goat anti-IL-1 at 1:200 in blocking 
buffer) for 1 h. After washing three times with PBS, the cells were 
stained with Alexa Fluor 555-conjugated goat anti-rabbit IgG (1:500 
in PBS) and with Alexa Fluor 488-conjugated donkey anti-goat 
IgG (1:500 in PBS) for 1 h. The cells were stained with 4′,6- 
diamidino-2-phenylindole (5 g/ml) for 5 min and then washed 
with PBS. The coverslips were mounted onto glass slides with 
fluorescent mounting medium (Dabco) and analyzed on an Olym-
pus FV1000 laser scanning confocal microscope (Tokyo, Japan).
Transmission electron microscopy
Cells were cultured on Permanox four chamber slides for dif-
ferent lengths of time. Cells were fixed with 1–2% glutaraldehyde 
for 30 min and then rinsed with PBS three times; they were then 
incubated in 1% osmium tetroxide with 1.5% potassium ferricya-
nide for 30 min and then rinsed with water. The cells were dehy-
drated by incubating them in 70% ethanol for 15 min twice, then 
95% ethanol for 15 min twice, and finally 100% ethanol for 20 
min. The cells were then incubated in ethanol and acetonitrile 
(1:1) for 10 min, then with acetonitrile for 10 min twice; next 
they were incubated in PolyBed 812 and acetonitrile (1:2) for 1 h, 
then with PolyBed 812 and acetonitrile (2:1) for 1 h, and within 
pure PolyBed 812 overnight. Cells were embedded in mold 48 h 
at 60°C, which was cut and examined by transmission electron 
microscopy; 50 cells in each group were examined.
Cellular cholesterol analysis
The intracellular total cholesterol and FC were measured by 
an intracellular cholesterol quantitation kit (Sigma-Aldrich) 
according to the manufacturer’s instructions. Briefly, macro-
phages were trypsinized with trypsin-EDTA followed by cen-
trifugation. The cell pellets were resuspended in a mix of 
chloroform:isoporpanol:IGEPAL CA-630 (7:11:0.1). The samples 
were centrifuged at 13,000 g for 10 min to remove insoluble ma-
terial. The organic phase was transferred to new tubes and air 
dried at 50°C for 30 min, followed by blowing the samples with 
nitrogen to remove organic solvent. The lipid was dissolved with 
200 l cholesterol assay buffer; 50 l of the reaction mix was 
added to each standard and sample well in a 96-well plate and 
incubated for 60 min at 37°C in the dark. The absorbance at OD 
570 nm was measured with a Spectra Max M5 microplate reader 
(Molecular Devices).
Plasma lipid analysis
Blood was obtained from mice following an overnight fast and 
the plasma was obtained by centrifugation of the blood at 4,000 g 
for 20 min. Plasma cholesterol and triglyceride levels were mea-
sured by enzymatic colorimetric assays with cholesterol reagent 
and triglycerides GPO reagent kits (Raichem, SanDiego, CA). 
Plasma cholesterol lipoprotein profiles were determined using a 
fast-performance LC system (AKTA purifier, GE Healthcare Bio-
sciences, Pittsburgh, PA) equipped with a Superose 6 10/300 GL 
column (GE Healthcare). Pooled mouse plasma (100 l) was 
loaded onto the column and eluted at a constant flow rate of 
0.5 ml/min with 1 mM sodium EDTA and 0.15 M NaCI. Fractions 
of 0.5 ml were collected and cholesterol concentration from each 
fraction was measured.
Atherosclerosis analysis
Hearts and aortas were dissected from mice and processed as 
described previously (35). The base of the heart containing the 
Macrophage cholesterol efflux
The cholesterol efflux assay was processed as previously de-
scribed (34). Attached mouse macrophages in 24-well plates were 
cultured in DMEM for 24 h followed by cholesterol-loading with 
100 g/ml AcLDL incorporated with 3H-cholesterol for 3 days. 
Then efflux medium (either FBS-free DMEM or DMEM contain-
ing 20 g/ml human apoAI or 50 g/ml human HDL) with the 
absence or presence of 10 M UA was added to initiate choles-
terol efflux for 24 h. 3H radioactivity in efflux medium and cells 
was counted using a Beckman LS6500 liquid scintillation counter 
(Beckman Coulter, Indianapolis, IN). Cholesterol efflux rate was 
calculated as the percentage of the radioactivity counts in the 
medium. 3H-labeled cholesterol was purchased from Perkin-
Elmer (Waltham, MA). AcLDL and human HDL were from Bio-
medical Technologies (Stoughton, MA).
Quantitative real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen, San 
Diego, CA) and reverse transcribed into cDNA using iScript™ 
Reverse Transcription Supermix (Bio-Rad Laboratories, Inc., 
Hercules, CA). Quantitative real-time PCR (qPCR) analysis was 
carried out using iQ™ SYBR® Green Supermix (Bio-Rad) on an 
Eppendorf Realplex2 mastercycler (Eppendorf, Hamburg, 
Germany). The primers used in qPCR were: mouse 18S RNA 
(internal control), 5′-CGCGGTTCTATTTTGTTGGT-3′(forward) 
and 5′-AGTCGG CATCGTTTATGGTC-3′(reverse); mouse IL-1, 
5′-GCCCAT CC T CTGTGACTCAT-3′ (forward) and 5′-AGGC CACA-
GGTATTTTGTCG-3′ (reverse); mouse BECN1, 5′-GGCCAATAA 
GATGGGTCTGA-3′ (forward) and 5′-GCTGCACACAGTC-
CAGAAAA-3′ (reverse); mouse Atg16l1, 5′-GGTGCCGTAG C-
TTTCTTGAG-3′ (forward) and 5′-ACTGTGTCC AGTGGG GAGAC-3′ 
(reverse); mouse Atg4c, 5′-GCATTCCTGTTTCCCAAAGA-3′ 
(forward) and 5′- AAACCCGAAAGTCCTCTGGT-3′ (reverse); 
mouse Atg5, 5′-AGATGGACAGCTGCACACAC-3′ (forward) and 
5′-GCTGGGGGACAATGCTAATA-3′ (reverse). Samples were 
amplified using the following program: 95°C for 10 min followed 
by 40 cycles of 95°C for 10 s, 60°C for 15 s, and 68°C for 20 s, and 
then a melting curve analysis from 60 to 95°C every 0.2°C. The 
abundance of each gene product was calculated by relative quanti-
fication, with values for the target genes normalized with 18S RNA.
Western blot
Protein samples were loaded onto SDS-PAGE gels for electro-
phoresis. The size-separated proteins were then transferred to 
nitrocellulose membranes (Amersham Biosciences, Piscataway, 
NJ). The indicated primary antibodies and HRP-conjugated sec-
ondary antibodies were used to detect target proteins. Signal was 
detected using an ECL kit (Bio-Rad). For stripping, membranes 
were submerged for 30 min at 55–60°C in a buffer containing 
100 mM 2-mercaptoethanol, 2% (v/v) SDS and 62.5 mM Tris-
HCl (pH 6.7), with agitation, and then were washed three times 
with PBST.
Measurement of cytokines in cell culture medium or 
serum
Cytokine protein concentrations in cell culture medium or se-
rum were measured by ELISA, using kits from eBioscience (San 
Diego, CA) following the manufacturer’s instructions. The mac-
rophage-conditioned culture medium was diluted by 30- to 180-
fold for the measurement. The 96-well microplates were read 
using a SpectraMax M5 microplate reader.
Immunofluorescence staining
Macrophages were seeded in 8-well chamber slides. Cells were 
fixed with 4% paraformaldehyde for 3 min at room temperature 
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showed that UA at 10 M was 2-fold more effective in in-
creasing LC3I/II expression than rapamycin at 100 nM 
(Fig. 1B).
The autophagy-enhancing effect of UA was also evident 
as observed by electron microscopy. As shown in Fig. 1C, 
UA-treated pMs had numerous double-membrane struc-
tures that were characteristic of nascent autophagosomes, 
autophagosomes, and autolysosomes, while much fewer of 
these structures were detected in control cells. Autophago-
somes and nascent autophagosomes could not be clearly 
distinguished in the micrographs. The structure indicated 
as “autophagosomes” could also be nascent autophago-
somes. In autolysosomes, the segregated organelles lose 
their distinct shape and are usually replaced by electron-
dense materials. The diameter of typical autophagosomes 
or autolysosomes is 0.5–2 m. These electron microscopy 
data have confirmed that UA induces autophagy in pMs.
To examine the mechanisms by which UA enhances 
macrophage autophagy, qPCR was performed and showed 
that in both mouse pMs and Raw264.7 cells, UA at 
10 M significantly increased the expression of autophagy-
related proteins Atg5 and Atg16L1, but not that of Atg4c 
and Beclin-1 (BECN1) (Fig. 1D, E). UA did not change 
LC3 mRNA expression in macrophages either (data not 
shown).
UA suppresses IL-1 production in macrophages
It has been reported that UA has anti-inflammatory ef-
fects on macrophages (26). To investigate the effects of 
UA on pro-inflammatory cytokines such as IL-1, IL-6, and 
TNF, pMs were treated with LPS (100 ng/ml) and/or 
UA (10 M) for 6 h, and the expression of the abovemen-
tioned cytokines was examined using qPCR. As shown in 
Fig. 2A and supplementary Fig. 1A, LPS significantly in-
creased the mRNA expression of IL-1, IL-6, and TNF; 
UA only slightly (without statistical significance) sup-
pressed LPS-induced expression of these cytokines. How-
ever, Western blot analysis showed that UA substantially 
reduced the pro-IL-1 protein level in both LPS-treated 
pMs and Raw264.7 cells (Fig. 2B).
We next examined whether UA suppresses mature 
IL-1 secretion. Mouse pMs were treated with LPS or 
Pam3CSK4 with or without UA for 16 h and the condi-
tioned medium was collected for ELISA measurement of 
IL-1 protein levels. The result showed that LPS and 
Pam3CSK4 stimulated the secretion of IL-1, whereas UA 
significantly inhibited the secretion of IL-1 (Fig. 2C). 
However, UA did not significantly reduce the secretion of 
IL-6 or TNF in LPS-treated mouse pMs (supplementary 
Fig. 1B).
To determine whether UA suppresses IL-1 production 
in vivo, we injected C57BL/6 mice intraperitoneally with 
either PBS (control), LPS alone, or LPS together with UA 
(50 mg/kg). Sixteen hours after injection, blood samples 
were taken for analysis of serum IL-1 concentration by 
ELISA. The results showed that LPS significantly increased 
serum IL-1 levels and UA significantly suppressed the 
induction (Fig. 2D). We developed a method to mea-
sure mouse serum UA concentration by coupling HPLC 
aortic root was embedded in OCT medium and frozen at 20°C. 
The aorta (from the ascending region to the abdominal region) 
was fixed in 10% neutral buffered formalin at room temperature 
overnight and then kept in PBS before removing the adventitia. 
For analysis of atherosclerosis in the aortic root, 10 m serial 
sections were collected. Atherosclerotic lesion areas of 10 serial 
sections were visualized with hematoxylin and eosin staining 
(hematoxylin: GeneTex, Inc., ready-to-use, catalog number 
GTX73341; eosin: Sigma-Aldrich, eosin B, catalog number 
861006-10G), and lipid-stained lesions were visualized by Oil Red 
O (ORO) staining and quantified by Image-Pro Plus 6.0. Rat 
anti-mouse moma2 (Abcam) was used for immunostaining for 
macrophage analysis on serial sections of the aortic root, and bio-
tinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, 
CA; catalog number BA-1000) was used as the secondary anti-
body. Immunoreactivity was amplified using the Vectastain ABC 
kit (Vector Laboratories, catalog number PK6100), and signal 
was enhanced by peroxidase enhancer (GeneTex, Irvine, CA; 
GTX82979) and finally reacted with the substrate from AEC 
Chromogen/FRP substrate kit (GeneTex; GTX82977). For col-
lagen staining of the lesions, the 10 m-thick aortic root sections 
were stained by Movat’s pentachrome using a Movat penta-
chrome stain kit from Scytek Laboratory (catalog number MPS-2; 
Logan, UT) following the manufacturer’s instructions, and vi-
sualized and analyzed by a Nikon NiU research microscope 
equipped with a NIS-Elements software package and a high reso-
lution CMOS color camera as well as Image-Pro Plus 6.0. The en 
face aortas were stained with ORO and the plaque areas were 
analyzed by ImageJ.
Statistical analysis
All data were summarized as mean ± SEM. To compare two 
groups on a continuous response variable (e.g., gene expression 
levels and atherosclerosis size), we used a t-test. To compare mul-
tiple groups on a continuous response variable, we used a one-
way ANOVA followed by Bonferroni post assay to compare the 
selected two groups. Normality and homoscedasticity were tested 
to ensure that parametric testing was appropriate. P  0.05 was 
considered statistically significant. GraphPad Prism 5 software 
was used to carry out all statistical analysis.
RESULTS
UA enhances macrophage autophagy
The structure of UA was confirmed by NMR; the purity 
was determined by mass spectroscopy and HPLC to be 
>98% (data not shown). Its cytotoxicity was measured by 
MTT assay. UA was dissolved in DMSO as a stock solution 
of 10 mM and then diluted into appropriate media. Mouse 
pMs and Raw264.7 cells were treated with 0–40 M UA 
for up to 5 days. Data showed that at concentrations up to 
10 M, UA did not cause any apparent cytotoxicity to both 
cell types, but it led to cell death at >30 M (data not 
shown). Therefore, we used UA at 10 M or lower for all 
the following experiments. To examine whether UA in-
creases macrophage autophagy, we treated mouse pMs 
with UA and Wortmannin (an autophagy inhibitor). UA-
enhanced autophagy was evidenced by increased LC3-I/II 
proteins, whereas Wortmannin completely blocked UA-
induced LC3 increase (Fig. 1A). Next, using Raw264.7 
cells, we confirmed UA’s autophagy-inducing activity. Data 
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The overlap between IL-1 and LC3 signals indicates that 
autophagy induced by UA may sequester pro-IL-1 in au-
tophagic vesicles.
UA promotes cholesterol efflux from lipid-loaded 
macrophages
Autophagy has been shown to enhance cholesterol ef-
flux to apoAI (12–14). To examine whether UA promotes 
macrophage cholesterol efflux by enhancing autophagy, 
we used mouse pMs to perform experiments using pre-
viously established protocol (35). We found that UA 
(10 M) significantly increased cholesterol efflux to apoAI, 
but not to HDL (Fig. 3A). An autophagic flux inhibitor, 
bafilomycin A1, completely diminished the cholesterol ef-
flux enhancement by UA (Fig. 3B). qPCR and Western 
blots showed that UA did not increase the mRNA expres-
sion and protein levels of ABCA1 and ABCG1 (Fig. 3C, D), 
indicating that the cholesterol efflux enhancing effects of 
UA are not caused by ABCA1 or ABCG1 induction.
To search for evidence of autophagic vacuoles in lipid-
loaded macrophages and, if present, whether these were 
associated with lipid droplets (LDs), electron microscopic 
analysis was performed. The results clearly showed that 
UA increased lipophagy in AcLDL-loaded macrophages 
(Fig. 3E). LDs were easily identifiable as round light-
density structures in AcLDL-loaded cells [Fig. 3E(b), white 
and mass spectroscopy; we found, after injection of UA at 
50 mg/kg, that serum UA concentration peaked at 12 M 
at 2 h post injection and dropped to below 3 M at 24 h 
post injection (data not shown).
A previous study demonstrated that autophagy inhibits 
inflammasome activation and IL-1 secretion in response 
to endotoxin (9). IL-1 is produced by activated macro-
phages as a proprotein (pro-IL-1), which is proteolytically 
processed to its active form by caspase 1. Inflammasome 
activation results in increased availability of caspase 1 and, 
therefore, accelerated process of pro-IL-1. Interestingly, 
we found that UA did not change the expression of cas-
pase 1 (data not shown). Other studies have shown that, in 
macrophages, autophagy may also regulate IL-1 secre-
tion by encapsulating and degrading pro-IL-1 in au-
tolysosomes (10). To examine whether UA promotes 
autophagic sequestration and degradation of pro-IL-1, 
we incubated Raw264.7 cells with UA and LPS, and de-
tected the intracellular location of IL-1 and LC3 by con-
focal microscopy. As shown in Fig. 2E, when Raw264.7 
cells were treated with LPS for 24 h, IL-1 staining in the 
cytosol was significantly greater compared with control; 
UA-treated cells had dramatically more autophagosomes 
(LC3 staining) than control or LPS-treated cells. When 
the cells were treated with LPS and UA, IL-1 staining be-
came weaker and appeared to be colocalized with LC3. 
Fig. 1. UA enhances macrophage autophagy. A: 
Western blot analysis of LC3 in cell lysates from pMs 
treated with UA (10 M) and Wortmannin (Wort, 500 
nM) for 6 h. B: Western blot analysis of LC3 in cell ly-
sates from Raw264.7 cells treated with UA (10 M) or 
rapamycin (100 nM) for 6 h. C: Electron microscopy 
images of pMs treated with control (Con) medium 
or UA (10 M). pMs were treated with UA (10 M) 
for 6 h and fixed for electron microscopy as described 
in the text. Black hollow arrows indicate nascent au-
tophagosomes; white hollow arrows indicate autopha-
gosomes; black solid arrow indicates an autolysosome; 
white solid arrows indicate mitochondria; N indicates 
nucleus. Scale bar indicates 2 m. D, E: The effects of 
UA (10 M) on the expression of autophagy-related 
genes in pMs (D) or Raw264.7 cells (E) treated for 6 h. 
*P < 0.05 versus control.
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could reduce atherosclerosis in mouse models. Female 
LDLR/ mice at an age of 8 weeks were randomly divided 
into two groups (9–10 mice per group) and fed a Western 
diet for 11 weeks. In the DMSO group, the mice were in-
jected intraperitoneally with vehicle (0.1% DMSO in 1 ml 
PBS) every other day; while in the UA group, the mice 
were injected with UA (50 mg/kg in 1 ml PBS with 0.1% 
DMSO) every other day. Food intake and body weight 
were measured weekly. We noticed that, while the food 
intake was not different between the two groups (supple-
mentary Fig. 2A), the body weights of the UA group mice 
were lower than the vehicle group in the first 3 weeks after 
the initiation of Western diet and UA treatment, but they 
caught up in the following weeks; at the endpoint, body 
weights of the two groups were not significantly different 
(supplementary Fig. 2B). The mice were euthanized and 
comprehensive analyses were performed to compare the 
two groups. We did not find any significant differences be-
tween the two groups of mice in total serum cholesterol 
(supplementary Fig. 2C), triglycerides (supplementary 
Fig. 2D), and fasting blood glucose (supplementary Fig. 2E), 
solid arrow] and UA reduced the number of LDs and in-
creased the frequency of LDs with areas of high density 
and asymmetrically localized multi-membrane structures, 
indicating that autophagosomes occur on the surface of 
the LDs [Fig. 3E(c), black solid arrow].
To examine whether UA increases cholesterol ester 
(CE) hydrolysis through enhancing autophagy, we mea-
sured total cholesterol and FC in mouse pMs loaded with 
50 g/ml AcLDL in the absence or presence of 10 M 
UA in serum-free DMEM for 24 h; and the CE and FC/CE 
ratio were calculated. We found that, while UA did not 
significantly reduce total cholesterol loading to the macro-
phages, it significantly increased the FC/CE ratio (Fig. 3F), 
indicating that UA, indeed, increased CE hydrolysis in 
macrophages.
UA attenuates atherogenesis in hypercholesterolemic 
mice
Because UA was shown to suppress macrophage IL-1 
production and secretion and enhance macrophage cho-
lesterol efflux, we next examined whether UA treatment 
Fig. 2. UA suppresses IL-1 secretion from macro-
phages via enhancing autophagy. A: UA did not in-
hibit LPS-induced IL-1 mRNA expression in mouse 
pMs. *P  0.05 versus control or UA. B: UA re-
duced pro-IL-1 protein levels in macrophages. C: UA 
reduced mature IL-1 secretion from macrophages. 
*P  0.05; **P  0.01. D: UA treatment reduced se-
rum IL-1 levels in LPS-treated mice. LPS (20 g per 
mouse, ip injection) increased the IL-1 level in se-
rum in mice and UA (50 mg/kg, ip injection) signifi-
cantly blunted the increase. *P  0.05. E: Confocal 
microscopy of Raw264.7 cells treated with UA (10 M) 
and/or LPS (100 ng/ml). Arrows point to LC-3 stain-
ing. Yellow dots (in merge image of LPS+UA group) in-
dicate colocalization of red (LC-3) and green (IL-1) 
signals in Raw264.7 cells. Scale bar: 5 m.
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significance (Fig. 4C). However, the collagen content (per-
centage) in the lesions, as determined by Movat’s penta-
chrome staining, was significantly larger in the UA group 
(22.9 ± 2.0%) than in the vehicle group (14.7 ± 2.6%) (Fig. 
4D). Furthermore, the atherosclerotic lesion area in en face 
aortas was significantly smaller in the UA group than in the 
vehicle group (supplementary Fig. 3B, C).
We also stained IL-1 and LC-3 in the aortic root slides 
to examine whether UA induced autophagy and reduced 
IL-1 in atherosclerotic lesions. The autophagy levels (re-
flected by LC-3 staining) in atherosclerotic lesions were 
increased in the UA group compared with the control 
group, especially in the macrophage-rich lesions. Mean-
while, the positivity of IL-1 was significantly decreased in 
the atherosclerotic lesions of the UA group compared with 
the control group. More interestingly, in the lesions of the 
UA group, there was significantly more IL-1 and LC-3 
overlapping (Fig. 5). Our results suggested that UA treat-
ment has increased autophagy in the atherosclerotic lesion, 
as well as pro-IL-1 degradation in the autophagosome.
DISCUSSION
In this study, we demonstrate that a phytonutrient, UA, 
enhances macrophage autophagy, suppresses macrophage 
as well as overall fast-performance LC lipoprotein profile 
(supplementary Fig. 2F, G). ELISA showed that IL-1 pro-
tein levels were reduced in the serum of the UA group 
compared with the control group, while the serum levels 
of IL-5 were not different between the two groups of mice 
(Fig. 4A). Interestingly, serum IL-6 and TNF levels were 
also significantly reduced in UA-treated mice (supplemen-
tary Fig. 2H). The reduction in these cytokines may be sec-
ondary to IL-1 reduction and the resulting reduced 
chronic systemic inflammation in mice.
The UA group of mice developed significantly less ath-
erosclerosis compared with the vehicle group. As visualized 
by hematoxylin and eosin staining, mean lesion area in the 
aortic root was 3.72 ± 0.27 and 6.01 ± 0.58 × 105 m2 in the 
UA group and the vehicle group, respectively, reflecting a 
38% reduction in the UA group (supplementary Fig. 3A). 
We further stained the aortic root lesions for neutral lipid 
with ORO. The results showed that the lipid staining area in 
the lesions of the UA group (3.91 ± 0.31 × 105 m2) was 
significantly smaller than that in the vehicle group (5.79 ± 
0.22 × 105 m2), with a 32% reduction (Fig. 4B). We stained 
lesional macrophages using a mouse macrophage-specific 
antibody, MOMA-2, and found that the UA group dis-
played a slightly lower percentage of macrophage area in 
aortic root atherosclerotic lesions compared with the vehicle 
group (63.4 ± 2.6% vs. 70.2 ± 2.7%), but without statistical 
Fig. 3. UA enhances macrophage cholesterol efflux 
through inducing lipophagy. A: Effects of UA (10 
M) on pM cholesterol efflux to DMEM (Control), 
apoAI, or HDL. Values are presented as mean ± SEM 
relative to DMSO control. *P < 0.05. B: The effect of 
UA on macrophage cholesterol efflux to apoAI was 
diminished by bafilomycin A1 (Baf). *P < 0.05. C, D: 
UA did not affect ABCA1 and ABCG1 mRNA expres-
sion (C) and protein levels (D) in cholesterol-loaded 
pMs. pMs were loaded with AcLDL, with or with-
out UA, ABCA1, and ABCG1 mRNA and protein levels 
were determined by qPCR or Western blot. Values are 
presented as mean ± SEM relative to vehicle control. 
E. Transmission electron microscopy images of pMs: 
control (a); AcLDL (b); AcLDL+UA (c). White ar-
rows, LDs; black arrows, LDs with areas of high den-
sity and asymmetrically localized multi-membrane 
structures; N, nucleus. Scale bar: 2 m. F: Total cellu-
lar cholesterol and FC/CE ratio were measured for 
mouse pMs loaded with AcLDL for 24 h in the 
absence or presence of UA.
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inhibitors at levels sufficient for autophagy induction in 
macrophages causes systemic immunosuppression. The 
characterization of UA as a macrophage autophagy in-
ducer in this study may add this natural compound as a 
new compound for clinical development toward a new 
anti-atherogenic agent. We show that UA enhances mac-
rophage autophagy by increasing mRNA expression of 
Atg5 and Atg16l1 and protein levels of LC3I and LC3II; 
electron microscopy confirmed that UA increases au-
tophagosome formation in macrophages. However, the 
more detailed molecular mechanisms warrant further in-
vestigation; for example, what targets UA directly binds 
to in the cell or on the cell membrane, and how UA mod-
ulates Atg5 and Atg16l1 expression, but not several other 
autophagy-related genes.
Macrophages contribute to atherogenesis by serving as 
inflammatory machinery and as a lipid deposit tank. Au-
tophagy has been shown to reduce macrophage inflam-
mation and foam cell formation by various mechanisms. 
In the arm of inflammation in the arterial intima, oxi-
dized lipids and other inflammatory stimuli provoke 
macrophages to produce a variety of inflammatory cyto-
kines, including IL-1, IL-6, and TNF-, among which IL-
1 plays a dominant role in the inflammatory cascade in 
the plaques. In this study, we show that UA significantly 
reduced intracellular pro-IL-1 levels and mature IL-1 
secretion in LPS-treated macrophages, although it did 
not reduce IL-1 mRNA expression. Increasing evidence 
suggests that autophagy is necessary to keep down the en-
dogenous sources of inflammasome and IL-1 activation 
(36). Macrophages derived from Atg16l1-deficient mice 
produced higher levels of IL-1 (9). Additional studies 
using cells of human origin demonstrated that the inhi-
bition of autophagy led to the upregulated production 
of IL-1 (37, 38). To examine how UA regulates IL-1 
production in macrophages, we used immunofluores-
cence confocal microscopy to observe colocalization of 
IL-1 and LC3 in Raw 264.7 cells after treatment by 
TLR ligands combined with UA. The overlap between 
IL-1 and LC3 indicated that autophagy induced by UA 
brought pro-IL-1 into the lumen of autophagic vacuoles 
for degradation, thereby reducing pro-IL-1 in the cells, 
which was usually processed by caspase 1 to generate ma-
ture IL-1 for secretion; although UA-induced autophagy 
did not suppress active caspase 1 generation through 
inflammasomes.
Oxidized or other modified LDL, unlike normal LDL, 
is readily taken up by the macrophage through scavenger 
receptors SR-A or CD36, resulting in the formation of 
macrophage foam cells. Accumulation of lipid-loaded 
macrophage foam cells is a central feature in the forma-
tion of atherosclerotic plaques (39, 40). Maintaining 
macrophage cholesterol homeostasis is essential for the 
prevention and treatment of atherosclerosis. In this 
study, we provide evidence that UA enhanced apoAI- 
mediated cholesterol efflux from macrophage foam 
cells through autophagy. Our data show that UA en-
hanced apoAI-mediated cholesterol efflux, which can be 
blocked by the autophagic flux inhibitor, bafilomycin A1. 
IL-1 secretion, and promotes cholesterol efflux from 
cholesterol-loaded macrophages. Furthermore, we show 
that administration of UA attenuates atherogenesis in hy-
perlipidemic mouse models. This represents the first re-
port that a natural compound suppresses atherosclerosis 
through a mechanism that is associated with macrophage 
autophagy enhancement.
Several recent studies have convincingly shown that 
macrophage autophagy plays a protective role against 
atherogenesis in mouse models. However, using macro-
phage autophagy induction as an anti-atherosclerosis 
strategy is a distant goal because none of the known au-
tophagy inducers or enhancers have been shown to be 
beneficial without reasonable side effects in preclinical 
studies. For example, systemic administration of mTOR 
Fig. 4. UA attenuates atherosclerosis in LDLR-deficient mice fed 
a Western diet. The mice were fed a Western diet for 11 weeks and 
administered vehicle or UA as described. The aortic roots were em-
bedded in OCT medium and frozen at 20°C immediately after 
being cut away from the aorta. For analysis of atherosclerosis, 10 
micron-thick sections were collected in the region of the proximal 
aorta, starting from the end of the aortic sinus. A: UA significantly 
reduced serum IL-1 levels, but did not significantly alter serum 
IL-5 levels in the mice. B: The lipid content in lesions was deter-
mined by ORO staining and quantified by Image-Pro Plus 6.0. The 
quantitative analysis and representative images are shown. C: The 
areas of macrophages in lesions were determined by immunostain-
ing for MOMA-2 (a macrophage marker). D: Trichrome staining 
for quantification of the lesion collagen content. Quantitative anal-
ysis and representative images are shown. Scale bar: 250 m.
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UA has anti-atherogenic effects on female LDLR/ mice 
induced to be diabetic and fed a high fat diet supple-
mented with UA for 11 weeks. The mechanism was sug-
gested to be monocyte recruitment suppression. Our 
results are in agreement with these findings because the 
absolute MOMA-2-stained area in the plaques of our 
LDLR/ mice was reduced, although the area percent-
age reduction did not reach statistical significance. On 
the other hand, Messner et al. (43) reported a UA dose-
dependent increase in atherosclerosis in Western diet-
fed male apoE/ mice receiving UA in drinking water 
for 24 weeks. The mechanisms were proposed to be en-
dothelial cell death induction and serum IL-5 reduction 
caused by UA consumption. In our study, we did not ex-
amine the endothelial proliferation and apoptosis in 
UA-treated mice, but did not observe a significant de-
crease of serum IL-5 levels in LDLR/ mice. As correctly 
pointed out by Tannock (44), all these studies, including 
ours, were designed differently, including the animal 
model, the UA administration route, the dose, and the 
duration, and the mechanistic studies evaluated different 
cell types. In our study, we administered UA using perito-
neal injection, avoiding the potential metabolism of UA 
in the gut and first pass effects in the liver. The plasma 
UA concentration determined in mice was 3–12 M 
within 24 h after a single injection, which is close to the 
concentrations we used in the in vitro macrophage ex-
periments, indicating that the macrophage autophagy-
enhancing mechanism identified in in vitro experiments 
can at least partially explain the anti-atherogenic effects. 
Indeed, we also directly observed enhanced autophagy 
in the plaques of UA-treated mice. Nevertheless, more 
studies are needed to confirm the effects of UA on ath-
erosclerosis and to more comprehensively examine the 
mechanisms.
In conclusion, our data suggest that UA enhances macro-
phage autophagy and thus reduces pro-IL-1 processing into 
mature IL-1, and promotes macrophage cholesterol efflux 
(as depicted in Fig. 6). Both of these effects are anti-
atherogenic, contributing to the attenuated atherogenesis in 
LDLR/ mice fed a Western diet. Our study provides evi-
dence that UA might be an optimal anti-atherogenic therapy 
by virtue of its macrophage autophagy-enhancing activity.
By doing so, UA did not increase ABCA1 and ABCG1 ex-
pression; instead, UA increased lipophagy in macro-
phages, evidenced by the fusion of autophagosomes with 
LDs in the electron microscopic images. Our finding that 
enhanced autophagy is associated with improved choles-
terol efflux from macrophages is consistent with previous 
reports (13, 14). It is worth noting that our electron mi-
croscopic images show that UA increased the frequency 
of LDs with areas of high density and asymmetrically lo-
calized multi-membrane structures. For larger LDs, au-
tophagosomes only engulfed a discrete part of the LDs, 
which then pinched off as membrane vesicles enriched 
in LC3 (autolipophagosomes), in this way autophago-
somes occur on the surface of these large organelles. 
Such partial engulfment of organelles by autophagy has 
been described for the nucleus and endoplasmic reticu-
lum (41, 42).
We further demonstrate that the beneficial effects 
of UA on macrophage inflammatory response and cho-
lesterol homeostasis translate well into atherosclerosis 
reduction in mouse models. We show that peritoneal 
injection of UA at 50 mg/kg once every other day in 
LDLR/ mice fed a Western diet for 11 weeks signifi-
cantly reduced atherosclerotic plaque formation. De-
tailed composition analysis for LDLR/ mice showed 
that UA reduced the overall lesion size, the lipid contain-
ing area, and the macrophage content, while it increased 
the collagen content, suggesting that UA treatment re-
sults in smaller and more stable lesions in mice. Further 
immunohistochemical analysis revealed that UA treat-
ment reduced IL-1 levels, but increased LC3 levels, 
in atherosclerotic plaque, and that UA significantly in-
creased the colocalization of IL-1 and LC3 in the lesions, 
indicating that UA, indeed, reduced IL-1 concentration 
in plaque through enhancing autophagy and IL-1 se-
questration and degradation in the autophagic pathway. 
ELISA data further confirmed the reduction of IL-1 in 
serum. These in vivo data demonstrate that the macro-
phage autophagy-inducing effects indeed confer UA with 
anti-atherogenic capacity.
There are two previous studies that investigated the ef-
fects of UA on atherosclerosis using mouse models that 
obtained opposite results. Ullevig et al. (31) showed that 
Fig. 5. UA increases IL-1 and LC3 colocalization 
in atherosclerotic lesions in mice. Representative fluo-
rescent microscopic images for detecting LC3/IL-1 
in aortic root sections are shown. The frozen tissue 
was stained with anti-LC3 and anti-IL-1 antibodies, 
as described in the Materials and Methods. White ar-
rows indicate colocalization of LC3 and IL-1. Scale 
bar: 200 m.
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